Kinarus stops midphase study in hospitalized COVID-19 patients early, adding to long list of failed trials

Kinarus Therapeutics is the latest company to swing and miss at the hospitalized COVID-19 opportunity. After seeing a who’s who of biopharma companies fail, the Swiss biotech has pulled the plug on a phase 2 trial in response to the lackluster efficacy data reviewed at an interim analysis.